

# Vassilios J Bezzerides

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7576200/publications.pdf>

Version: 2024-02-01

38  
papers

1,426  
citations

430874

18  
h-index

361022

35  
g-index

40  
all docs

40  
docs citations

40  
times ranked

2367  
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Prevalence of Premature Truncating Variants in Plakophilin-2 and Association With Arrhythmogenic Right Ventricular Cardiomyopathy: A UK Biobank Analysis. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, 101161CIRCGEN121003507.	3.6	5
2	Two sides of the same coin: new insights into mechanisms of ventricular fibrillation. <i>Cardiovascular Research</i> , 2021, 117, 983-984.	3.8	2
3	Drug screening platform using human induced pluripotent stem cell-derived atrial cardiomyocytes and optical mapping. <i>Stem Cells Translational Medicine</i> , 2021, 10, 68-82.	3.3	23
4	Increased Reactive Oxygen Species-Mediated Ca <sup>2+</sup> /Calmodulin-Dependent Protein Kinase II Activation Contributes to Calcium Handling Abnormalities and Impaired Contraction in Barth Syndrome. <i>Circulation</i> , 2021, 143, 1894-1911.	1.6	42
5	Abstract 13290: Childhood-Onset Arrhythmogenic Cardiomyopathy Associated With Genetic Variants in Desmoplakin. <i>Circulation</i> , 2021, 144, .	1.6	0
6	Inhibition of mTOR Signaling Enhances Maturation of Cardiomyocytes Derived From Human-Induced Pluripotent Stem Cells via p53-Induced Quiescence. <i>Circulation</i> , 2020, 141, 285-300.	1.6	72
7	Risk Factors for Early Recurrence Following Ablation for Accessory Pathways. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008848.	4.8	7
8	Paediatric/congenital cardiology physician scientists—An endangered species. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13367.	3.4	1
9	CITED4 Protects Against Adverse Remodeling in Response to Physiological and Pathological Stress. <i>Circulation Research</i> , 2020, 127, 631-646.	4.5	29
10	Clinical and Genetic Findings in Children Presenting With Ventricular Fibrillation as the First Manifestation of Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e016322.	3.7	3
11	AAV Gene Therapy Prevents and Reverses Heart Failure in a Murine Knockout Model of Barth Syndrome. <i>Circulation Research</i> , 2020, 126, 1024-1039.	4.5	62
12	Low mortality in fetal supraventricular tachycardia: Outcomes in a 30-year single-institution experience. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1105-1113.	1.7	23
13	Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population. <i>Heart Rhythm</i> , 2020, 17, 984-990.	0.7	6
14	Value of provocative electrophysiology testing in the management of pediatric patients after congenital heart surgery. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 901-907.	1.2	0
15	Gene therapy for inherited arrhythmias. <i>Cardiovascular Research</i> , 2020, 116, 1635-1650.	3.8	20
16	MICAL1 constrains cardiac stress responses and protects against disease by oxidizing CaMKII. <i>Journal of Clinical Investigation</i> , 2020, 130, 4663-4678.	8.2	23
17	Phenotypic Manifestations of Arrhythmogenic Cardiomyopathy in Children and Adolescents. <i>Journal of the American College of Cardiology</i> , 2019, 74, 346-358.	2.8	63
18	Insights Into the Pathogenesis of Catecholaminergic Polymorphic Ventricular Tachycardia From Engineered Human Heart Tissue. <i>Circulation</i> , 2019, 140, 390-404.	1.6	105

#	ARTICLE	IF	CITATIONS
19	Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia by Inhibition of Ca <sup>2+</sup> /Calmodulin-Dependent Kinase II. <i>Circulation</i> , 2019, 140, 405-419.	1.6	81
20	Activin type II receptor signaling in cardiac aging and heart failure. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	95
21	Phenotypic Characterization of Individuals With Variants in Cardiovascular Genes in the Absence of a Primary Cardiovascular Indication for Testing. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002463.	3.6	3
22	The Real-World Utility of the LINQ Implantable Loop Recorder in Pediatric and Adult Congenital Heart Patients. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 245-251.	3.2	30
23	Differentiation of fasciculoventricular fibers from anteroseptal accessory pathways using the surface electrocardiogram. <i>Heart Rhythm</i> , 2019, 16, 1072-1079.	0.7	21
24	Exercise Testing in the Management of Arrhythmias. , 2019, , 235-255.		0
25	Low molecular weight heparin as an anticoagulation strategy for left-sided ablation procedures. <i>Congenital Heart Disease</i> , 2018, 13, 222-225.	0.2	3
26	Utility of incomplete right bundle branch block as an isolated ECG finding in children undergoing initial cardiac evaluation. <i>Congenital Heart Disease</i> , 2018, 13, 419-427.	0.2	8
27	Mitochondrial Cardiomyopathy Caused by Elevated Reactive Oxygen Species and Impaired Cardiomyocyte Proliferation. <i>Circulation Research</i> , 2018, 122, 74-87.	4.5	89
28	Genotype-phenotype-guided medical and surgical intervention in long QT syndrome. <i>HeartRhythm Case Reports</i> , 2018, 4, 14-17.	0.4	2
29	Dual-Site Ventricular Pacing in Patients With Fontan Physiology and Heart Block. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 1289-1297.	3.2	17
30	Channelopathy as a SUDEP Biomarker in Dravet Syndrome Patient-Derived Cardiac Myocytes. <i>Stem Cell Reports</i> , 2018, 11, 626-634.	4.8	37
31	Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders. <i>Scientific Reports</i> , 2017, 7, 346.	3.3	22
32	Modeling Inherited Arrhythmia Disorders Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Circulation Journal</i> , 2017, 81, 12-21.	1.6	11
33	Acetylation of VGLL4 Regulates Hippo-YAP Signaling and Postnatal Cardiac Growth. <i>Developmental Cell</i> , 2016, 39, 466-479.	7.0	86
34	Pausing With the Gauze. <i>Anesthesia and Analgesia</i> , 2016, 123, 1143-1148.	2.2	7
35	CITED4 induces physiologic hypertrophy and promotes functional recovery after ischemic injury. <i>JCI Insight</i> , 2016, 1, .	5.0	63
36	miR-222 Is Necessary for Exercise-Induced Cardiac Growth and Protects against Pathological Cardiac Remodeling. <i>Cell Metabolism</i> , 2015, 21, 584-595.	16.2	316

#	ARTICLE	IF	CITATIONS
37	Phenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 72, 74-84.	1.9	40
38	Saying Yes to Exercise and NO to Cardiac Injury. <i>Circulation Research</i> , 2011, 108, 1414-1416.	4.5	9